Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/17/?d=1Neue Studien: Europe PMCdeHuman Dermal Fibroblast-derived Spheroids Demonstrate Efficacious Immune Modulation in a Psoriasis Mouse Modelhttps://www.psoriasis-news.de/articles.html/1_articles/human-dermal-fibroblast-derived-spheroids-demonstrate-efficacious-immune-modulation-in-a-psoriasis-mouse-model-r176/Background: Psoriasis is a chronic inflammatory disease associated with high morbidity and few cases of sustained remission. Innovative immunomodulatory therapies, including fibroblast-based cell therapies, offer promising alternatives. This study investigates the therapeutic potential of human dermal fibroblasts (HDFs) organized into three-dimensional (3D) spheroids in a mouse model of imiquimod (IMQ)-induced psoriasis. Methods HDF spheroids were cultured using Elplasia microcavity plates, and their size, viability, and phenotype were compared with single cells in 2D monolayer cultures. Cellular responses in whole blood and acute inflammatory responses were evaluated at various time points following intravenous injection of HDFs. The therapeutic efficacy of HDF spheroids was assessed using an IMQ-induced psoriasis mouse model, with disease severity scored using the Psoriasis Area and Severity Index (PASI). Optimized HDF spheroids (~150 um, 1x106 cells/mouse) were administered intravenously in a single dose for mild psoriasis or multiple doses for moderate-to-severe psoriasis. The efficacy of HDF spheroids was compared to a pre-clinical monoclonal antibody targeting interleukin 23 (anti-IL-23). Results Spheroid cultures of HDFs showed reduced cell size, enhanced viability, and distinct phenotypic changes compared to monolayer cultures. Intravenous injection of HDF spheroids resulted in less thrombocytopenia and reduced acute inflammatory responses compared to single-cell injection. A single dose of HDF spheroids reduced the severity of mild psoriasis by 35%, while repeated doses resulted in a 36% reduction in moderate-to-severe psoriasis. Single-dose administration normalized blood cell counts, alleviated spleen enlargement, and improved cytokine dysregulation. Although HDF spheroids and anti-IL-23 reduced epidermal thickening and immune cell infiltration, HDF spheroids uniquely inhibited monocyte production and infiltration, a benefit not observed with anti-IL-23. No acute or chronic toxicity was observed. Conclusions HDF spheroids offer comparable therapeutic efficacy to anti-IL-23 in treating psoriasis, with a distinct mechanism involving inhibiting monocyte production and infiltration. Their safety profile and broader immunomodulatory potential support their development as a novel therapeutic strategy for psoriasis and other inflammatory diseases.

Weiterlesen

]]>176Sun, 10 Aug 2025 12:04:09 +0000Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024.https://www.psoriasis-news.de/articles.html/1_articles/composite-outcome-measures-for-psoriatic-arthritis-project-updates-2024-r175/Weiterlesen

]]>175Sun, 10 Aug 2025 12:04:09 +0000Representation of Psoriasis on the Web for Patients With Skin of Color.https://www.psoriasis-news.de/articles.html/1_articles/representation-of-psoriasis-on-the-web-for-patients-with-skin-of-color-r174/UnlabelledThis study analyzed over 2000 images of psoriasis across major web-based platforms and found a significant underrepresentation of darker skin tones, highlighting a critical gap in dermatologic representation that may contribute to misdiagnoses and health disparities among patients with skin of color.

Weiterlesen

]]>174Sun, 10 Aug 2025 12:04:09 +0000Gender differences in the association between adverse childhood experiences and early onset psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/gender-differences-in-the-association-between-adverse-childhood-experiences-and-early-onset-psoriasis-r173/Weiterlesen

]]>173Sun, 10 Aug 2025 12:04:09 +0000Non-communicable diseases comorbidities negatively impact the treatment outcomes among psoriasis patients: a longitudinal study in Shanghai, China.https://www.psoriasis-news.de/articles.html/1_articles/non-communicable-diseases-comorbidities-negatively-impact-the-treatment-outcomes-among-psoriasis-patients-a-longitudinal-study-in-shanghai-china-r172/BackgroundPsoriasis is frequently associated with non-communicable disease (NCD) comorbidities, prompting interest in how these concurrent conditions may influence psoriasis treatment outcomes.

Objectives

To assess NCD prevalence and their influence on psoriasis treatment outcomes.

Methods

From 2022 to 2024, we recruited psoriasis patients in Shanghai Skin Disease Hospital. Data on demographic features, NCD comorbidities and treatment outcomes at week 4 and week 8 were systematically collected through questionnaire, physical examination, and clinical severity assessment (psoriasis area and severity index [PASI], body surface area [BSA], physician's global assessment [PGA]).

Results

Among 1116 patients, 48.4% had at least one NCD comorbidity. NCD-free patients exhibited higher PASI50 response rates at both week 4 (46.5 vs. 39.1%) and week 8 (72.2 vs. 70.9%). Log binomial regression revealed that NCDs significantly reduced the likelihood of achieving PASI50 at week 4 (relative risk [RR] = 0.84, 95% confidence interval [CI]: 0.73-0.96), with a similar but non-significant trend at week 8 (RR = 0.98, 95% CI: 0.92-1.06).

Conclusion

NCDs negatively impact early treatment outcomes in psoriasis patients. So we propose that dermatologists should integrate systematic NCD management into psoriasis treatment regimen.

Weiterlesen

]]>172Mon, 04 Aug 2025 07:43:04 +0000Real-World Effectiveness of Bimekizumab in Predominantly Difficult-to-Treat Patients with Psoriatic Arthritis Followed in a Combined Dermatology-Rheumatology Clinic: A 24-Week Multicenter Study.https://www.psoriasis-news.de/articles.html/1_articles/real-world-effectiveness-of-bimekizumab-in-predominantly-difficult-to-treat-patients-with-psoriatic-arthritis-followed-in-a-combined-dermatology-rheumatology-clinic-a-24-week-multicenter-study-r171/IntroductionBimekizumab (BKZ), a monoclonal antibody targeting interleukin (IL)-17A and IL-17F, has shown high efficacy in clinical trials. However, real-world data on its use in psoriatic arthritis (PsA) are limited. This study aimed to evaluate the effectiveness and safety of BKZ over 24 weeks in a real-world setting.

Methods

A retrospective, multicenter study was conducted at two Italian rheumatology centers, enrolling adult patients with PsA who initiated BKZ treatment between January 2023 and February 2025. Clinical data were collected at baseline, week 12, and week 24.

Results

Forty patients with PsA were included. Of these, 75% had failed at least two biologic and/or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) prior to BKZ and 25/40 (62.5%) had failed at least one IL-17A inhibitor (IL-17Ai). Among these 25 patients, 32% experienced a primary failure and 68% a secondary failure. The median baseline Disease Activity in Psoriatic Arthritis (DAPSA) score was 22.9 (17.5-27.2), decreasing to 6.0 (3.1-12.8) at week 24 (p < 0.001). By week 24, 72.5% achieved DAPSA low disease activity (LDA), and 25% achieved DAPSA remission. The median swollen joint count (SJC) decreased from 3.0 (0.8-5.3) to 0.0 (IQR 0.0-1.0), and median tender joint count (TJC) decreased from 4.5 (3.0-7.3) to 1.0 (0.0-2.0) (both p < 0.001). Pain visual analog scale (VAS) and Patient Global Assessment (PGA) improved significantly, from 7.0 (6.0-8.0) and 7.5 (6.5-8.0) at baseline to 2.0 (1.0-5.0) and 2.0 (1.0-4.5) at week 24 (both p < 0.001). Skin involvement also improved, with 51.5% achieving Psoriasis Area and Severity Index (PASI) 100 by week 24. The safety profile was favorable; 15% of patients developed mild oral candidiasis, none of which required treatment discontinuation.

Conclusion

BKZ demonstrated rapid and sustained improvements in PsA symptoms in a challenging real-world population, with a favorable safety profile.

Weiterlesen

]]>171Mon, 04 Aug 2025 07:43:04 +0000The Burden of Pediatric Psoriasis: A Systematic Review.https://www.psoriasis-news.de/articles.html/1_articles/the-burden-of-pediatric-psoriasis-a-systematic-review-r170/BackgroundThe approach to pediatric psoriasis requires special considerations, given the potential for negative consequences on overall physical and psychosocial health.

Objective

The aim of this study was to systematically review the literature to characterize the burden of pediatric psoriasis.

Methods

Papers assessing associations between pediatric psoriasis (in children <18 years old) and quality of life, physical symptoms (e.g., skin pain, itch, sleep disruption), and adverse psychological, social, and financial effects were searched with no date restrictions through July 2023. Databases searched included Ovid MEDLINE®, CENTRAL, the Cochrane Database of Systematic Reviews, and PsycInfo. Articles were excluded if they focused on comorbidities (including psoriatic arthritis/enthesitis), were of low quality, or were not in English.

Results

64 publications met eligibility criteria. Composite quality of life was the most frequently reported domain (40 publications) and was negatively impacted by psoriasis as a function of severity. Physical burdens, especially itch, occurred in 44.1-96.3% of children with psoriasis, while skin pain was less common. Psychosocial and family burdens were less frequently assessed and often with non-validated tools. Children with psoriasis participated less in social activities, but there were no clear associations between psoriasis and school performance or interpersonal relationships. Psoriasis was associated with a higher mental health burden on caregivers and greater family financial burden.

Conclusions

Psoriasis leads to high burden for pediatric patients and caregivers. Evaluation and management decisions should include and incorporate a thorough assessment of burden. Additional studies using validated tools are necessary to fully assess psychosocial and family burdens of psoriasis.

Weiterlesen

]]>170Mon, 04 Aug 2025 07:43:04 +0000Dietary Principles, Interventions and Oxidative Stress in Psoriasis Management: Current and Future Perspectives.https://www.psoriasis-news.de/articles.html/1_articles/dietary-principles-interventions-and-oxidative-stress-in-psoriasis-management-current-and-future-perspectives-r169/Weiterlesen

]]>169Mon, 04 Aug 2025 07:43:04 +0000Psoriasis Beyond the Skin: A Disease With Cardiovascular Risk.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-beyond-the-skin-a-disease-with-cardiovascular-risk-r168/Weiterlesen

]]>168Mon, 04 Aug 2025 07:43:04 +0000Family planning and pregnancy among patients with psoriasis: incorporating the patients' voice in healthcare practice and information provision.https://www.psoriasis-news.de/articles.html/1_articles/family-planning-and-pregnancy-among-patients-with-psoriasis-incorporating-the-patients-voice-in-healthcare-practice-and-information-provision-r167/Aim: Having psoriasis and being treated with medication could raise concerns regarding family planning and pregnancy (FPP), and no guidelines are available on healthcare practice and information provision regarding FPP for these patients. This study aims to gain insight in the perspectives of patients with psoriasis on this important subject.Methods: A cross-sectional questionnaire study including adult female and male patients with psoriasis, independent of their treatment type.Results: A total of 102 patients responded to the questionnaire (70% females, 30% males), of whom 47.1% have ever used biologic therapy. Respondents preferred dermatologists or general practitioners (GPs) as information provider. Patients would like to receive FPP information on fertility, heredity of psoriasis, use of psoriasis medication, and - specifically for females- the course of psoriasis during and after pregnancy and breastfeeding. Timing of FPP information provision was preferable at moment of diagnosis and medication changes or upon explicit request.Conclusion: Dermatologists and GPs have a crucial role in providing FPP information. The findings of this study have provided hands-on guidance for healthcare professionals to improve healthcare for both female and male patients with psoriasis in the reproductive age.

Weiterlesen

]]>167Mon, 04 Aug 2025 07:43:04 +0000Greater topical corticosteroid quantity applied reduces severity of psoriasis: Results from two randomized controlled trials.https://www.psoriasis-news.de/articles.html/1_articles/greater-topical-corticosteroid-quantity-applied-reduces-severity-of-psoriasis-results-from-two-randomized-controlled-trials-r166/BackgroundTopical drugs containing corticosteroids are recommended first-line treatment for patients with mild-moderate psoriasis. However, the optimal recommended dosage of topical drugs has not been well established.

Objectives

To investigate the effect of topical drug application quantity and treatment duration on psoriasis treatment outcome.

Methods

We conducted a post-hoc analysis of two randomized controlled trials investigating 214 patients with psoriasis using topical drugs containing corticosteroids and/or calcipotriol for up to 48 weeks. We measured the amount of topical drugs used during the study period and calculated the mean amount of applied drugs per 1% affected body surface area (BSA) divided by number of days in the study period. Improvement in severity of psoriasis was measured by Lattice-System Physician's Global Assessment (LS-PGA) (where affected BSA was divided into seven categories) from baseline to last study visit. Descriptive results were reported as counts with proportions, and as means with normality-based confidence intervals (CI). Associations were analyzed using linear regressions.

Results

Most study participants had a duration of psoriasis greater than 20 years, moderate psoriasis, and no history of using systemic psoriasis treatment. They had applied a mean of 1.0 g per 1% BSA per day (95% CI 0.9; 1.2). Daily use of topical drugs for four-weeks reduced severity of psoriasis. However, extended daily use for up to 48 weeks provided further reduction in disease severity (coefficient --0.30 (95% CI -0.51, -0.09)) and -0.73 (95% CI -1.09; -0.38) (P= 0.028). Greater amount of applied topical drugs reduced severity of psoriasis in a linear manner. Every increase of 1 g of topical drugs applied per 1% BSA per day reduced LS-PGA by 0.43 (95% CI 0.24; 0.61). Finally, patients who had never used systemic drugs experienced a greater reduction in psoriasis when applying the same mean amount of topical drugs (coefficient -0.7 (95% CI -1.1, -0.4) compared to those who had a history of taking systemic treatment (-0.3 (95% CI -0.5; -0.1), P=0.026).

Conclusions

A mean application amount of at least 1.0 g of topical drugs per 1% BSA per day seems safe and effective and can be used daily until clearance.

Weiterlesen

]]>166Mon, 04 Aug 2025 07:43:04 +0000Apremilast in Psoriasis: Current Landscape and Perspectives.https://www.psoriasis-news.de/articles.html/1_articles/apremilast-in-psoriasis-current-landscape-and-perspectives-r165/Weiterlesen

]]>165Mon, 04 Aug 2025 07:43:04 +0000Therapeutic Potential of Mesenchymal Stem Cells in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/therapeutic-potential-of-mesenchymal-stem-cells-in-psoriasis-r164/Weiterlesen

]]>164Mon, 04 Aug 2025 07:43:04 +0000Copay Accumulators: A Legislative Issue in Dermatology.https://www.psoriasis-news.de/articles.html/1_articles/copay-accumulators-a-legislative-issue-in-dermatology-r163/No abstract supplied.

Weiterlesen

]]>163Mon, 04 Aug 2025 07:43:04 +0000Real-World Effectiveness and Safety of Risankizumab in Psoriasis: A Comprehensive Analysis from the Saudi Arabia Psoriasis Registry (PSORSA).https://www.psoriasis-news.de/articles.html/1_articles/real-world-effectiveness-and-safety-of-risankizumab-in-psoriasis-a-comprehensive-analysis-from-the-saudi-arabia-psoriasis-registry-psorsa-r154/IntroductionPsoriasis is a chronic immune-mediated skin condition that has a substantial impact on patients' quality of life. The Saudi Arabia Psoriasis Registry (PSORSA) was established to address long-term real-world data (RWD) on systemic and biologic therapies in the region. This observational cohort study provides a comprehensive analysis of baseline disease characteristics, comorbidities, and treatment efficacy among patients enrolled in PSORSA, with an emphasis on risankizumab.

Methods

Data were sourced from a governmental online database covering multiple healthcare centers. Patients eligible for biologics were followed at baseline and at weeks 16, 28, 40, and 52 to evaluate disease severity, quality of life, and adherence. Statistical analyses were conducted using Jamovi and R. Descriptive statistics were performed for categorical and continuous variables. p-Values < 0.05 were considered significant.

Results

The study cohort included 313 patients. Plaque psoriasis was the most prevalent clinical type (93.9%). An analysis of treatment history revealed that 39.6% of patients had prior therapy exposure, and all patients received risankizumab as a biologic therapy. At baseline, the mean Psoriasis Area and Severity Index (PASI) score was 25.49. By week 52, it had decreased to 0.358, indicating complete clearance. PASI scores showed a steady and substantial reduction over time, with an 88% reduction at week 16, 96% at week 28, 97.5% at week 40, and 98.5% by week 52, demonstrating a strong and sustained treatment effect (p < 0.001). Additionally, risankizumab exhibited a favorable drug survival profile, with many patients maintaining treatment beyond 122 weeks.

Conclusion

This study represents the first real-world assessment of risankizumab for moderate-to-severe psoriasis in Saudi Arabia. The findings demonstrate that risankizumab is an effective and well-tolerated treatment for moderate-to-severe psoriasis in this Saudi Arabian cohort. However, future studies should explore long-term safety outcomes and the comparative effectiveness of risankizumab and emerging biologics in diverse patient populations.

Weiterlesen

]]>154Thu, 31 Jul 2025 12:43:37 +0000Biologic and small molecule therapies for psoriasis in individuals with Down syndrome: Two cases and a systematic review.https://www.psoriasis-news.de/articles.html/1_articles/biologic-and-small-molecule-therapies-for-psoriasis-in-individuals-with-down-syndrome-two-cases-and-a-systematic-review-r153/Weiterlesen

]]>153Thu, 31 Jul 2025 12:43:37 +0000Correction to "Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry".https://www.psoriasis-news.de/articles.html/1_articles/correction-to-impact-of-delay-of-treatment-with-disease-modifying-antirheumatic-drugs-in-psoriatic-arthritis-the-corevitas-psoriatic-arthritisspondyloarthritis-registry-r152/No abstract supplied.

Weiterlesen

]]>152Thu, 31 Jul 2025 12:43:37 +0000A Validated Quantitative LC-MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study.https://www.psoriasis-news.de/articles.html/1_articles/a-validated-quantitative-lc-msms-method-for-determination-of-deucravacitinib-in-rat-plasma-and-its-application-to-a-pharmacokinetic-study-r151/2 = 0.9976). The intraday and interday precisions were less than 6.62% and 5.95%, respectively, with accuracies ranging from 90.68% to 103.80%. The recovery of deucravacitinib ranged from 95.34% to 103.80% and remained stable under different conditions. After successful validation, the method was used for pharmacokinetic profiling of deucravacitinib in rats following oral administration.

Weiterlesen

]]>151Thu, 31 Jul 2025 12:43:37 +0000Greater topical corticosteroid quantity applied reduces severity of psoriasis: Results from two randomized controlled trials.https://www.psoriasis-news.de/articles.html/1_articles/greater-topical-corticosteroid-quantity-applied-reduces-severity-of-psoriasis-results-from-two-randomized-controlled-trials-r150/Weiterlesen

]]>150Thu, 31 Jul 2025 12:43:37 +0000IL-17A inhibitors modulate skin microbiome in psoriasis: implications for microbial homeostasis.https://www.psoriasis-news.de/articles.html/1_articles/il-17a-inhibitors-modulate-skin-microbiome-in-psoriasis-implications-for-microbial-homeostasis-r149/BackgroundThe IL-17A inhibitors target aberrant immune responses in psoriasis but also impacts the host's defense against infections. The effects of this treatment on skin microorganisms and microbiome-encoded metabolic pathways remain unclear.

Objectives

This was an exploratory clinical study designed to investigate whether Psoriasis is associated with skin microbiota, as well as a longitudinal cohort study aimed at revealing the effects of IL-17A inhibitor treatment on skin microbiota in Psoriasis.

Methods

In this study, we recruited 26 patients with moderate to severe psoriasis and 15 healthy controls. We collected skin microbiome samples from both greasy and dry skin regions. All samples were analyzed using 16S rDNA gene sequencing to determine the microbial profiles.

Results

Compared with healthy controls, the composition and function of skin microbiome in psoriasis patients are heterogeneous. Treatment with IL-17A inhibitors significantly increases the alpha diversity of the skin microbiota in psoriasis patients, indicating potential restoration of microbial community richness and evenness. However, this treatment does not entirely alter the taxonomic composition of the skin microbiota; rather, it shifts the relative abundance of specific microbial species, indicating that certain core microbial features remain relatively stable. Moreover, IL-17A inhibitors help adjust the functional profile of the skin microbiome in psoriasis patients, bringing it closer to that of healthy individuals.

Conclusions

Psoriasis patients exhibit significant heterogeneity in both the composition and functionality of their skin microbiota. Although IL-17A inhibitor treatment fails to fundamentally alter its taxonomic composition, this therapy effectively enhances microbial community stability by increasing alpha diversity and modulating the relative abundance of various taxa. Additionally, it adjusts the functional profile of the skin microbiota towards a healthier state, thereby contributing to the restoration of microecological balance.

Weiterlesen

]]>149Thu, 31 Jul 2025 12:43:37 +0000Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis.https://www.psoriasis-news.de/articles.html/1_articles/successful-treatment-with-secukinumab-in-a-psoriasis-patient-on-hemodialysis-r148/Weiterlesen

]]>148Thu, 31 Jul 2025 12:43:37 +0000Copay Accumulators: A Legislative Issue in Dermatologyhttps://www.psoriasis-news.de/articles.html/1_articles/copay-accumulators-a-legislative-issue-in-dermatology-r147/No abstract supplied.

Weiterlesen

]]>147Thu, 31 Jul 2025 12:43:37 +0000Treatment of severe psoriasis in a hospice care patient using secukinumab, an inhibitor of interleukin-17A expression: Treatment response and changes in quality of life.https://www.psoriasis-news.de/articles.html/1_articles/treatment-of-severe-psoriasis-in-a-hospice-care-patient-using-secukinumab-an-inhibitor-of-interleukin-17a-expression-treatment-response-and-changes-in-quality-of-life-r146/Weiterlesen

]]>146Thu, 31 Jul 2025 12:43:37 +0000Correction to “Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry”https://www.psoriasis-news.de/articles.html/1_articles/correction-to-impact-of-delay-of-treatment-with-disease%E2%80%90modifying-antirheumatic-drugs-in-psoriatic-arthritis-the-corevitas-psoriatic-arthritisspondyloarthritis-registry-r145/No abstract supplied.

Weiterlesen

]]>145Thu, 31 Jul 2025 12:43:37 +0000Recent advancement of fisetin-based nanoformulations in the management of psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/recent-advancement-of-fisetin-based-nanoformulations-in-the-management-of-psoriasis-r143/Weiterlesen

]]>143Sat, 12 Jul 2025 18:34:11 +0000